Use of maintenance therapy and complete discontinuation for therapeutic management of non-resectable metastatic colorectal cancer

被引：1

作者：

Senellart, Helene ^{[1
]}

Hiret, Sandrine ^{[1
]}

Guerin-Meyer, Veronique ^{[2
]}

Bennouria, Jaafar ^{[1
]}

机构：

[1] Inst Cancerol Ouest, Med Oncol Serv, F-44805 St Herblain, France

[2] Inst Cancerol Ouest, Med Oncol Serv, F-49933 Angers 9, France

来源：

BULLETIN DU CANCER | 2014年 / 101卷 / 06期

关键词：

metastatic colorectal cancer; chemotherapy complete discontinuation; maintenance therapy; chemotherapy free interval; PHASE-III TRIAL; 1ST-LINE TREATMENT; CHEMOTHERAPY; OXALIPLATIN; BEVACIZUMAB; FLUOROURACIL; INTERMITTENT; LEUCOVORIN; CETUXIMAB; COMBINATION;

D O I：

10.1684/bdc.2014.1984

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Management of unresectable metastatic colorectal cancer dramatically changed over the past 20 years. News standards of care combine cytotoxic drugs like fluoropyrimidines, irinotecan and oxaliplatin, with targeted therapies such as anti-EGFR monoclonal antibodies and anti-angiogenic agents. Survival benefit results from these new options but correlates with more exposure to chemotherapy and cumulative toxicities. The main concern for these patients remains to find the optimal balance between efficacy, toxicity and quality of life. This article reviewed the main studies designed to evaluate the concept of maintenance therapy after induction chemotherapy and discontinuation strategy. Available therapeutic standards and options to shorten duration of chemotherapy and reduce toxicities are reported and discussed.

引用

页码：619 / 625

页数：7

共 26 条

[1] Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial [J].

Adams, Richard A. ;

Meade, Angela M. ;

Seymour, Matthew T. ;

Wilson, Richard H. ;

Madi, Ayman ;

Fisher, David ;

Kenny, Sarah L. ;

Kay, Edward ;

Hodgkinson, Elizabeth ;

Pope, Malcolm ;

Rogers, Penny ;

Wasan, Harpreet ;

Falk, Stephen ;

Gollins, Simon ;

Hickish, Tamas ;

Bessell, Eric M. ;

Propper, David ;

Kennedy, M. John ;

Kaplan, Richard ;

Maughan, Timothy S. .

LANCET ONCOLOGY, 2011, 12 (07) :642-653

[2]

[Anonymous], J CLIN ONCOL

[3] Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer [J].

Bokemeyer, Carsten ;

Bondarenko, Igor ;

Makhson, Anatoly ;

Hartmann, Joerg T. ;

Aparicio, Jorge ;

de Braud, Filippo ;

Donea, Serban ;

Ludwig, Heinz ;

Schuch, Gunter ;

Stroh, Christopher ;

Loos, Anja H. ;

Zubel, Angela ;

Koralewski, Piotr .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (05) :663-671

[4] Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study [J].

Cappuzzo, Federico ;

Ciuleanu, Tudor ;

Stelmakh, Lilia ;

Cicenas, Saulius ;

Szczesna, Aleksandra ;

Juhasz, Erzsebet ;

Esteban, Emilio ;

Molinier, Olivier ;

Brugger, Wolfram ;

Melezinek, Ivan ;

Klingelschmitt, Gaelle ;

Klughammer, Barbara ;

Giaccone, Giuseppe .

LANCET ONCOLOGY, 2010, 11 (06) :521-529

[5] Can Chemotherapy Be Discontinued in Unresectable Metastatic Colorectal Cancer? The GERCOR OPTIMOX2 Study [J].

Chibaudel, Benoist ;

Maindrault-Goebel, Frederique ;

Lledo, Gerard ;

Mineur, Laurent ;

Andre, Thierry ;

Bennamoun, Mostepha ;

Mabro, May ;

Artru, Pascal ;

Carola, Elisabeth ;

Flesch, Michel ;

Dupuis, Olivier ;

Colin, Philippe ;

Larsen, Annette K. ;

Afchain, Pauline ;

Tournigand, Christophe ;

Louvet, Christophe ;

de Gramont, Aimery .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (34) :5727-5733

[6] First-Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III MACRO TTD Study [J].

Diaz-Rubio, Eduardo ;

Gomez-Espana, Auxiliadora ;

Massuti, Bartomeu ;

Sastre, Javier ;

Abad, Albert ;

Valladares, Manuel ;

Rivera, Fernando ;

Safont, Maria J. ;

Martinez de Prado, Purificacion ;

Gallen, Manuel ;

Gonzalez, Encarnacion ;

Marcuello, Eugenio ;

Benavides, Manuel ;

Fernandez-Martos, Carlos ;

Losa, Ferran ;

Escudero, Pilar ;

Arrivi, Antonio ;

Cervantes, Andres ;

Duenas, Rosario ;

Lopez-Ladron, Amelia ;

Lacasta, Adelaida ;

Llanos, Marta ;

Tabernero, Jose M. ;

Anton, Antonio ;

Aranda, Enrique .

ONCOLOGIST, 2012, 17 (01) :15-25

[7] Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study [J].

Douillard, Jean-Yves ;

Siena, Salvatore ;

Cassidy, James ;

Tabernero, Josep ;

Burkes, Ronald ;

Barugel, Mario ;

Humblet, Yves ;

Bodoky, Gyoergy ;

Cunningham, David ;

Jassem, Jacek ;

Rivera, Fernando ;

Kocakova, Ilona ;

Ruff, Paul ;

Blasinska-Morawiec, Maria ;

Smakal, Martin ;

Canon, Jean-Luc ;

Rother, Mark ;

Oliner, Kelly S. ;

Wolf, Michael ;

Gansert, Jennifer .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (31) :4697-4705

[8]

Falcone A, 2013, J CLIN ONCOL, V31

[9]

Grothey A, 2008, J CLIN ONCOL, V26, p4010a

[10] A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer [J].

Hecht, J. Randolph ;

Mitchell, Edith ;

Chidiac, Tarek ;

Scroggin, Carroll ;

Hagenstad, Christopher ;

Spigel, David ;

Marshall, John ;

Cohn, Allen ;

McCollum, David ;

Stella, Philip ;

Deeter, Robert ;

Shahin, Seta ;

Amado, Rafael G. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (05) :672-680

← 1 2 3 →